Manchin, Kaine, Warner Call for Investigation into FDA Decision on Oxycontin
In a letter to the Health, Education, Labor and Pensions Committee, the Senators are calling for an investigation into the decision to approve OxyContin for children as young as 11-years-old
Washington, D.C. – U.S. Senators Joe Manchin (D-WV), Tim Kaine (D-VA) and Mark Warner (D-VA) today sent a letter to the Health, Education, Labor and Pensions (HELP) Committee Chairman Lamar Alexander (R-TN) and Ranking Member Patty Murray (D-WA) calling for an investigation into the Food and Drug Administration’s (FDA) decision to approve OxyContin for use by children as young as 11-years-old and an examination of the rise in the opioid misuse, abuse and consequent overdose deaths.
“The decision by the FDA to prescribe OxyContin to children as young as 11-years-old is a horrifying example of the disconnect between the agency’s approval process and the realities the deadly epidemic of prescription drug abuse are having on our communities,” Senator Manchin said. “The Senate must act swiftly to examine this decision, which was made without the advice of an independent advisory committee, and take a look at the opioid abuse epidemic more broadly.”
“In August, I traveled across the Commonwealth and heard from local leaders, law enforcement, and medical professionals about the impact opioid abuse is having on our communities,” said Senator Kaine. “The over prescription and misuse of opioids has contributed to the drug abuse crisis, and I’m deeply concerned that FDA’s decision to approve OxyContin for children as young as 11-years-old will further complicate this epidemic.”
“The exponential rise in opioid abuse is devastating Virginia and the rest of the country. I am troubled by the FDA’s decision to expand the approved population who use these addictive drugs to include children as young as 11 years old. I’m especially concerned that this decision was made without the advice of an independent advisory committee, which is required by FDA regulations in cases like these,” Senator Warner said. “A comprehensive investigation will provide accountability and transparency about how this decision was reached.”
The letter was also signed by Senators Jeanne Shaheen (D-NH), Bill Nelson (D-FL), Ed Markey (D-MA), Kelly Ayotte (R-NH), Angus King (I-ME) and Claire McCaskill (D-MO).
Please read the full text of the Senators’ letter below or here.
Dear Chairman Alexander and Ranking Member Murray:
We write to urge the U.S. Senate Committee on Health, Education, Labor and Pensions to hold hearings on the exponential rise in the misuse and abuse of opioid painkillers and consequent opioid overdose deaths as well as examine the Food and Drug Administration’s (FDA) recent decision to approve a frequently abused prescription opioid painkiller known as OxyContin for use by children as young as 11 years old.
Today, there are 2.1 million Americans abusing or dependent on opioids. In addition, 44 people die every day as a result of a prescription opioid overdose. Abuse of opioid painkillers is also linked to abuse of heroin, increased hepatitis C infection rates, increase in HIV transmission and a host of other negative public health outcomes. The increased use and abuse of opioid medications is destroying lives and devastating communities. As we work to stop this crisis, the FDA’s decision to approve the use of OxyContin in pediatric patients is a step in the wrong direction, as it may lead to an increase in inappropriate prescribing and use among a population that are already at a higher risk for developing dependency and addiction. The United States Senate must act swiftly to examine this issue and protect a new generation from losing their productive lives to an opioid use disorder.
While other agencies of our government, including the Centers for Disease Control, the National Institute on Drug Abuse, and the Substance Abuse and Mental Health Services Administration, are speaking loudly about the desperate need to stop the overprescribing of opioids and scourge of related overdose deaths, the FDA has continued to approve and expand the populations who use these addictive and deadly drugs. The FDA’s most recent action, which will increase the likelihood that children as young as 11 years old will be prescribed OxyContin, is a troubling example of the disconnect between the FDA approval process and the realities of this deadly epidemic.
While the approval may be intended to be narrow, the trends of the last decade show us that there are likely to be far-reaching consequences. This decision does not increase access to these drugs for young cancer patients or other chronically ill patients who may need this drug, as pediatricians already prescribe medications that are not specifically approved for use in children when it is needed. Instead, the FDA’s actions give the producer of OxyContin – a company that, in 2007, pled guilty and paid $635 million in fines for deceiving doctors regarding the addictiveness of OxyContin – the legal right to begin advertising to pediatricians about the use of OxyContin to treat 11-16 year olds under certain circumstances. We have seen the devastating impact of this targeted advertising as the number of opioid prescriptions quadrupled between 1999 and 2012. Sadly, this increase has been accompanied by a quadrupling in the number of opioid overdose deaths.
Furthermore, this FDA decision was made without the advice of an independent advisory committee. Under the FDA’s own regulations, the agency is required to convene an advisory committee when a matter is of significant public interest, highly controversial, or in need of a specific type of expertise. It is our opinion that this decision meets every single one of those criteria. Given the extraordinary public health crisis that our country is facing and the well-documented damage that dangerously addictive drugs like OxyContin can do to a developing brain, an independent advisory board would have been most useful in aiding FDA in making an appropriate assessment of this decision. The lack of an advisory board and the potential consequences of the FDA’s decision make this an issue ripe for Congressional oversight and in need of a thorough examination by the United States Senate.
The American people are drowning under the weight of the prescription opioid abuse epidemic. We are losing too many Americans – young and old – and robbing many, many more of their potential. We must do everything in our power to stop the flow of these devastating drugs into our communities.
We strongly urge you to hold hearings into this decision and the public health impacts of the opioid abuse epidemic more broadly. As United States Senators, it is our duty to ensure that the federal government is protecting the citizens of this country, and ensuring that any medications approved by the FDA meet the strictest safety standards. We look forward to working with you to protect our children – and their parents and grandparents – from the scourge of opioid addiction.
###
Next Article Previous Article
